Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Open Access
- 11 June 2018
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Blood Cancer Journal
- Vol. 8 (6), 55
- https://doi.org/10.1038/s41408-018-0081-8
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- A call for action: Increasing enrollment of untreated patients with higher‐risk myelodysplastic syndromes in first‐line clinical trialsCancer, 2017
- Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesBritish Journal of Haematology, 2016
- Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United StatesLeukemia & Lymphoma, 2016
- Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatmentBlood Cancer Journal, 2016
- Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosidesLeukemia, 2015
- Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registryLeukemia, 2015
- Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemiaLeukemia Research, 2014
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeBritish Journal of Haematology, 2011
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineBlood, 2011
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009